Key points
- There are numerous human studies and randomized clinical trials for thymosin alpha-1.
- It can modulate the immune response via T-cell function, dendritic cells, Toll-like receptor signaling, and antigen presentation.
- A large multicenter Phase 3 sepsis study in 2025 showed no significant reduction in overall 28-day mortality; different response signals were reported in some predefined subgroups.
- A 2025 meta-analysis found a signal for mortality reduction in the pooled analysis in sepsis, but this advantage was not statistically clear in sub-analyses of high-quality and multicenter studies.
- A Cochrane chronic hepatitis B review dated September 9, 2026, evaluated the certainty of evidence as low or very low for many clinical outcomes.
What is Thymosin Alpha-1?
Tα1 is a 28-amino-acid peptide derived from natural prothymosin alpha. Its pharmacological form is also known as thymalfasin. Rather than simply “stimulating” the immune system, it can exert regulatory effects at multiple levels, such as T-cell maturation, antigen presentation, and innate immune signaling.
How is it thought to work?
Research indicates that Tα1 may have effects on Toll-like receptors, dendritic cell function, T-cell differentiation, and cytokine responses. For this reason, it has been investigated theoretically in different clinical conditions where the immune response is suppressed or dysregulated. However, the immune system behaves differently depending on the disease; the same peptide is not expected to yield the same outcome in every context of infection, autoimmune disease, or cancer.
How extensive is human research?
A comprehensive 2024 narrative review evaluated Tα1 data from more than 30 studies and over 11,000 participants across different clinical areas. This extensive literature demonstrates that the molecule has been studied in humans for a long time. However, study designs, disease groups, concomitant standard treatments, doses, and outcome measures are quite heterogeneous; therefore, each indication should be evaluated with its own high-quality data.
Sepsis research
Sepsis is one of the critical illness areas where Tα1 has been most intensively studied. In the 22-center, double-blind, randomized Phase 3 TESTS study published in the BMJ in 2025, 1,089 patients were analyzed, and no overall difference was demonstrated between Tα1 and placebo in terms of 28-day all-cause mortality. In contrast, signals of different treatment effects were observed in some predefined subgroups, such as age and diabetes.
A 2025 systematic review and meta-analysis evaluated 11 randomized trials and reported a signal for reduction in 28-day mortality in the pooled analysis. However, when high-quality and multicenter studies were examined separately, the statistical advantage was not clear; trial sequential analysis indicated that the current total sample size may be insufficient for definitive conclusions. This picture suggests not that Tα1 is “ineffective” in sepsis, but rather that it is not yet clear which patient subgroup may benefit.
Chronic hepatitis B
Tα1 has a long research history in hepatitis B. An updated Cochrane review published on September 9, 2026, reported that the certainty of efficacy was low or very low for outcomes such as mortality, serious adverse events, HBV-related morbidity, and quality of life in chronic hepatitis B. Therefore, it should not replace current standards of antiviral therapy.
Oncology and other infection areas
Tα1 has been investigated as an immunomodulatory approach in addition to standard therapy in different cancers and as a supportive treatment in various viral/bacterial infections. Some studies have reported signals of clinical or immunological benefit. However, because tumor types, treatment regimens, the patient’s immune status, and the endpoints used differ, a general conclusion that it “strengthens immunity in cancer” cannot be established. Oncological use should only be evaluated within the relevant oncology plan.
Route of administration
Subcutaneous administration was used in a significant portion of human clinical trials. Data of the same breadth and standardization do not exist for IV use. Because pharmacokinetics, peak concentration, and safety profile may also change when the route of administration changes, SC data should not be directly extrapolated to IV use.
Safety
Tα1 has generally demonstrated a well-tolerated profile in clinical trials; injection site reactions and mild systemic complaints may be reported. However, the clinical context of immunomodulation is particularly important in individuals undergoing transplantation, with active autoimmune disease, or receiving immunosuppressive therapy and oncological treatment. In compounded products, apart from the molecule itself, purity, sterility, stability, and product standardization must be evaluated.
Our approach at our Bodrum clinic
We evaluate thymosin alpha-1 not as a routine “immune-boosting serum,” but as an immunomodulatory molecule where an answer to a specific clinical question is sought. When its use comes up for consideration, the patient’s diagnosis, standard treatment, immune status, presence of autoimmunity or malignancy, current medications, and route of administration are evaluated together. We distinguish areas where research data is strong or where there are promising subgroups from areas where the data remains inconclusive.
Frequently asked questions
Does thymosin alpha-1 boost immunity?
“Boosting immunity” is an oversimplified expression. Tα1 modulates various components of the immune response; its clinical benefit varies depending on the disease and the individual’s immune status.
Is it beneficial in sepsis?
There are positive signals in the overall literature; however, the large 2025 Phase 3 study did not demonstrate an overall mortality advantage. Current research focuses on which patient subgroups might derive greater benefit.
Is IV thymosin alpha-1 standard?
The vast majority of human studies are based on subcutaneous administration. Routine IV use is not supported by the same level of standardized clinical data.
Related content
- Main Guide to Peptide Applications
- Functional Medicine
- Healthy Aging and Longevity
- IV and Serum Applications
References
- Wu J, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ. 2025. PMID: 39814420.
- Gu J, et al. Efficacy of thymosin α1 for sepsis: systematic review and meta-analysis of randomized controlled trials. 2025. PMID: 40969554.
- Naing C, et al. Thymosin-α1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026 Sep 9. PMID: 42713852.
- Dinetz E, Lee E. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. 2024. PMID: 38308608.
Written and medically reviewed by: Dr. Kerem Çağlayan
Last medical review: September 10, 2026
Disclaimer: This content is for general medical informational purposes only; it does not replace individual diagnosis or treatment recommendations.
